Red blood cell reagents
Active Awarded Last action
- Contract number
- FA282323F0022
- Awardee
-
Alba Bioscience, Inc. UEI V6KNKL6BDHL7
- Awarding agency
-
Air Force Test Center
Air Force Materiel Command, Department of Defense
- Obligated
- $62,943
Award facts
- Contract value 80% obligated
-
- $62,943.16 Current, with exercised options
- $78,678.95 Potential, with all options
- Completion date 78% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Eglin AFB, FL 32542, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $15,736 | |
| Exercise an Option | $15,736 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $15,736 | |
| Original award | $15,736 |
About this award
The Defense Health Agency awarded a delivery order to Alba Bioscience, Inc. for red blood cell reagents valued at $78,678.95 under a firm fixed price contract type. The contract, awarded December 2, 2022, has an ultimate completion date of November 30, 2027, and will be performed at Eglin Air Force Base in Florida. This procurement supports the federal healthcare system's blood banking operations through Alba Bioscience's specialized portfolio of immunohematology reagents, including monoclonal antibodies, antibody identification and screening panels, quality control kits, and cellular reagents. The award was made without set-aside designation, reflecting competitive procurement based on the vendor's specialized capabilities in in vitro diagnostic products essential for transfusion services.
Alba Bioscience, Inc., a Chicago-based subsidiary of Quotient Biodiagnostics, Inc., maintains this delivery order under the GSA Schedule for In Vitro Diagnostics, Reagents, and Tests (FSS-65-VII). The company has established itself as a critical supplier to multiple federal healthcare agencies, including the Defense Logistics Agency and Department of Veterans Affairs, leveraging its expertise in blood banking materials and diagnostic testing. The company currently holds two blanket purchase agreements with the Veterans Administration valued at approximately $418,512 combined, demonstrating sustained federal demand for its specialized blood banking products across integrated healthcare systems nationwide.
Quick answers
Who was awarded contract FA282323F0022?
FA282323F0022 was awarded to Alba Bioscience, Inc. by Air Force Test Center (Air Force Materiel Command) on December 2, 2022.
How much is contract FA282323F0022 worth?
The government has obligated $62,943 on FA282323F0022. Its potential value, with all options, is $78,679.
Is contract FA282323F0022 an order under another contract?
Yes. FA282323F0022 is a delivery order under 36F79721D0259, a federal supply schedule, on Invitro Diagnostics, Reagents, Test (FSS-65-VII).
Was contract FA282323F0022 competed?
The extent of competition for FA282323F0022 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award